TRIM15 Mediates ubiquitination of Paxillin to facilitate the progression of ovarian cancer Authors: Jiaqi Xu, Tiantian Wu, Fei Wu, Yue Zhu, Meng Liu, Yan Zhang, Wenxin Gao, Weifeng Qian, Guannan Feng, Xiaoyan Huang, Xiaoxue Xi, Shunyu Hou Published: 2026 ABSTRACT AbstractBackgroundGlobally, among gynecological malignancies, ovarian cancer (OC) stands as an important factor contributing to mortality. E3 ubiquitin ligase activity is a common characteristic found in the tripartite motif (TRIM) proteins, contributing significantly to post-translational modifications of various proteins. Among these TRIM proteins, TRIM15 has been linked to multiple cancer types. Nevertheless, the function of TRIM15 concerning OC has yet to be elucidated. We aimed to explore the role of TRIM15 in OC and shed light on the underlying mechanisms thereof.MethodsA bioinformatics analysis was conducted to investigate the variance in TRIM15 expression between normal ovarian tissues and OC tissues, and to explore the prognostic significance of TRIM15 in patients with OC. TRIM15 protein expression in OC tissues was detected using immunofluorescence. The impact of TRIM15 silencing and overexpression on the proliferation and migration of OC cells was assessed through various functional experiments, such as CCK-8, colony formation, and Transwell assays. Mass spectrometry analysis was performed to identify TRIM15-interacting substrates. The mechanism underlying substrate ubiquitination mediated by TRIM15 was further explored.ResultsBased on The Cancer Genome Atlas (TCGA) data and immunofluorescence analysis, OC tissues exhibited significant upregulation of TRIM15 expression. si-RNA-mediated silencing of TRIM15 suppressed the in vitro proliferation and migration of OVCAR3 and A2780 cells. Paxillin was selected as an interacting protein with TRIM15 by mass spectrometry. Mechanically, we discovered that TRIM15 mediated the ubiquitination of Paxillin via Lys11- and Lys29-linked polyubiquitin chains. Subsequent co-IP experiments revealed that TRIM15 could also enhance the interactions between Paxillin and its tyrosine kinase, FAK, thereby promoting the phosphorylation of Paxillin.ConclusionsWe revealed a previously unknown mechanism by which TRIM15 ubiquitinates and phosphorylates Paxillin to promote OC progression. These findings suggest that targeting TRIM15 holds promise as a therapeutic approach to treat OC.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12935-026-04260-z.Keywords: TRIM15, Ovarian cancer, Paxillin, Ubiquitination, Phosphorylation, FAK Introduction Globally, among gynecological malignancies, ovarian cancer (OC) stands as an important factor contributing to mortality [1]. The late detection, chemoresistance, and heterogeneity of OC contribute to poor patient prognosis [2]. Therefore, studying the pathogenesis of OC is crucial in identifying potential molecular therapeutic targets. The tripartite motif (TRIM) family comprises highly conserved proteins with really interesting new gene (RING) structural domains that exhibit E3 ubiquitin ligase activity [3]. Consequently, the majority of TRIM proteins exhibit E3 ubiquitin ligase activity, enabling them to modify a wide range of proteins through post-translational mechanisms [4, 5]. The TRIM protein family holds significant importance in a broad spectrum of biological processes and is implicated in numerous pathological conditions, encompassing transcriptional regulation, cellular growth, apoptosis, development, and the initiation of oncogenesis [4, 6]. TRIM15, an esteemed and evolutionarily conserved constituent of the TRIM protein family, traces its evolutionary origins to ancestral mammalian genomes—with orthologs identified across most mammalian species (e.g., mouse, rat, and primates) and sequence identity exceeding 85% between human and mouse TRIM15, reflecting strong selective pressure to retain its functional relevance [6]. The human TRIM15 gene is localized to specific genomic regions characterized by high evolutionary conservation and frequent involvement in disease-associated copy number variations, further underscoring its potential importance in maintaining biological homeostasis [6]. Structurally, TRIM15 retains the canonical tripartite motif architecture of the TRIM family—including an N-terminal RING domain (critical for E3 ubiquitin ligase activity), B-box domains (mediating protein oligomerization), and a coiled-coil domain (facilitating protein-protein interactions)—a structural feature conserved throughout its evolutionary history [3, 6]. TRIM15, an esteemed constituent of the TRIM protein family, has emerged as a significant player in various cancer types, including gastric adenocarcinoma, colorectal cancer, non-small cell lung cancer, and several others [7–10], exhibiting potential as a tumor suppressor or diagnostic marker. Nevertheless, the involvement of TRIM15 in OC remains unknown and requires further elucidation. We, therefore, aimed to explore the role of TRIM15 in OC and shed light on the underlying mechanisms thereof. We demonstrate that the downregulation of TRIM15 expression in OC cells has a suppressive effect on their migratory and proliferative capacities. Mass spectrometry analysis and western blot revealed a potential interaction between TRIM15 and Paxillin. Additionally, we discovered the indispensable role of TRIM15 in the ubiquitination and phosphorylation processes of Paxillin. Materials and methods Bioinformatics analysis We employed Gene Expression Profiling Interactive Analysis (GEPIA) to assess the variation in TRIM15 expression between ovarian and normal tissues. Additionally, a survival analysis for TRIM15 was conducted using the Kaplan–Meier plotter website. Subsequently, the DESeq2 processing package was employed to analyze the gene expression profiles, which were represented in count data format, to identify differences between the two groups. Genes that exhibited a significant fold change of |logFC|>0.585 and a p-value < 0.05 were considered TRIM15-related differentially expressed genes. The 3D structural models of proteins were download from the AlphaFold database, including PXN (AF-P49023-F1-model_v4) and TRIM15 (AF-Q9C019-F1-model_v4). The blind docking of PXN and TRIM14 was performed by using the local version of HDOCK. Cell culture and transient transfection The human ovarian cancer cell lines, namely OVCAR3 and A2780, were procured from Zhong Qiao Xin Zhou Biotechnology Co. (Shanghai, China). The cell lines have been authenticated using Short Tandem Repeat (STR) analysis and performed regular mycoplasma-free tests. The cells were cultured in complete medium consisting of RPMI-1640 medium (Meilunbio, China), fetal bovine serum (FBS) (ABW, Shanghai, China), and 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA), under optimal conditions of 37 °C with 5% CO2. Specifically, the A2780 requires 10% FBS while the OVCAR3 requires 20% FBS. For transfection, small interfering RNAs (siRNAs) targeting TRIM15 and negative control (Tsingke Biotech Co., China) were transiently transfected using Lipofectamine 2000 (Invitrogen). The specific sequences of the siRNA were provided below: the negative control (si-NC) 5′-UUCUCCGAACGUGUCACGU-3′; si-TRIM15-1# 5′-GCUUCUACAAGAUGUCAGA-3′; si-TRIM15-2# 5′-GGAUGUAAAGUGUCAAGAA-3′. TRIM15, Paxillin, and ubiquitin overexpression (oe) plasmids were constructed by Shanghai Sangon Biotechnology Co. OC cells were transfected with X-treme GENE HP DNA Infection Reagent (Mannheim, Germany) using a plasmid-to-reagent ratio of 1:3. For all DNA/RNA transfections, cells were collected for subsequent in vitro experiments 48 h after transfection. RNA extraction and quantitative reverse transcription polymerase chain reaction (RT-qPCR) Trizol reagent was utilized to extract total RNA from the cells. Subsequently, the RNA underwent reverse transcription using a specific reagent. RT-qPCR was carried out using SYBR qPCR SuperMix Plus (Novoprotein Scientific Inc., China) to quantify the relative expression of TRIM15 (F: 5′-ACTTGAGTCTCGAACAGCGG-3′; R: 5′-CGTCTGTGGTTCTGCACTCT-3′). The expression levels were normalized to 18s RNA (F: 5′-AAACGGCTACCACATCCAAG-3′; R: 5′-CCTCCAATGGATCCTCGTTA-3′) using the 2−ΔΔCT method. Cell proliferation assay Each well of a 96-well plate was seeded with 2,500 post-transfected cells. Cell viability was evaluated every 24 h using the Cell Counting Kit-8 (CCK8; Beyotime Biotechnology), and the absorbance at 450 nm was measured using a microplate reader, as previously described [11–13]. For colony formation assays, 48 h after transient transfection with siRNAs, cells were seeded in a six-well plate and incubated for 2 weeks with fluid changes every 7 days. Cells were then washed twice with phosphate-buffered saline (PBS) solution, fixed in methanol, and stained with a 0.1% crystal violet solution (Beyotime Biotechnology). Finally, the cell colonies were photographed and counted, as previously described [14, 15]. Cell migration assay The evaluation of cell migration capacity was performed by utilizing a Transwell chamber equipped with a membrane of 8-µm pore size, as previously described [16, 17]. In short, the upper chamber was supplemented with a total of 45,000 cells that had undergone transfection, suspended in 300 µl of medium devoid of serum. Simultaneously, the lower chamber was supplemented with 700 µl of complete medium. Following a 48-h incubation period, the cells that had successfully migrated to the undersurface of the membrane were meticulously fixed, stained, and subsequently rinsed. Immunofluorescence The tissue sections were deparaffinized using xylene, and rehydrated using a graded series of ethanol, as previously described [18, 19]. Following antigen retrieval in a sodium citrate buffer and subsequent blocking in 1% BSA/PBS for 2 h. The sections were incubated overnight at 4 °C with the specified primary antibodies. After that, the slides were washed using phosphate-buffered saline and treated with Alexa-fluor secondary antibody (1:500 dilution, Thermo Scientific, Waltham, MA, USA) for 1 h at room temperature in a dark environment. To visualize the cell nuclei, staining was performed using 4’,6-diamidino-2-phenylindole (DAPI). Finally, the samples were mounted and imaged using a Zeiss laser fluorescence microscope (Carl Zeiss, Germany). The antibodies utilized in this experiment included rabbit anti-TRIM15 antibody (1:200 dilution, Proteintech) and mouse anti-Ki67 antibody (1:200 dilution, Abcam). The OC tissue microarray was obtained from Zhongke Huaguang Biotech Co., Ltd. (Xi’an, China). Liquid chromatography/mass spectrometry (LC/MS) analysis OVCAR3 cells were transfected with Flag-TRIM15 plasmid and, 48 h later, the cells were lysed using RIPA lysate. Flag-TRIM15 was then precipitated utilizing anti-FLAG magnetic beads. The immunoprecipitated proteins were subsequently analyzed by LC/MS to identify TRIM15-interacting proteins, as previously described [20, 21]. Immunoprecipitation (IP) For 2 h, cell lysates were subjected to incubation with Dynabeads Protein A (Invitrogen) at a temperature of 4 °C. Subsequently, each sample was incubated overnight with anti-IgG antibody (Proteintech), anti-GFP beads (Proteintech), or anti-FLAG beads (SIGMA). On the following day, IgG samples underwent an additional incubation with Dynabeads Protein A at 4 °C for 3 h. In contrast, samples containing Flag and GFP magnetic beads did not require further incubation. The magnetic beads were retained and washed with the lysates three times. The Flag and GFP magnetic beads were then resolved in elution buffer containing 1% SDS and heated at 100 °C for 10 min. Finally, the immunoprecipitation products were detected using specific antibodies through western blotting. Ubiquitination assays After transfection with the specified plasmids, the cells were left to incubate for 48 h. Prior to sample collection, cells were treated with 20 µM MG132 for 6 h. RIPA lysate was used for cell lysis, and protease activity was inhibited by the addition of PMSF. Paxillin-GFP was immunoprecipitated using anti-GFP magnetic beads. Detection of TRIM15 was achieved using an anti-Flag antibody, whereas anti-GFP and anti-HA antibodies were utilized for the detection of Paxillin and Ubiquitin, respectively. Western blotting Total proteins were extracted by lysing cells using RIPA lysis buffer (Beyotime) supplemented with 1% phenylmethylsulfonyl fluoride (PMSF, Beyotime) as a protease inhibitor. To denature the proteins, they were heated at 100 °C for 10 min. The denatured proteins (20 µg per sample) were separated by SDS-polyacrylamide gel (GenScript, China). The proteins were transferred onto the polyvinylidene difluoride membranes (Millipore, Billerica, USA) and blocked with 5% nonfat milk for 1 h. The membranes were then incubated overnight (12–16 h) at 4 °C with specific primary antibodies. The membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (1:3,000 dilution) for 1 h at room temperature. The visualization of protein bands was performed using an enhanced chemiluminescent substrate as previously described [22–25]. Table 1 contains detailed information about the primary antibodies. Table 1Antibodies informationAntigenSourceCompanyDilutionTRIM15RabbitProteintech1:500GAPDHMouseProteintech1:3000PaxillinRabbitProteintech1:1000Phospho-Paxillin (Tyr118)RabbitCell Signaling Technology1:1000FAKRabbitProteintech1:500Phospho-FAK (Tyr397)RabbitCell Signaling Technology1:1000GFPRabbitAbcam1:1000FLAGMouseSigma1:1000HAMouseSanta Cruz Biotechnology1:500 Antibodies information Statistical analysis The analysis of the data was conducted utilizing GraphPad Prism software. All results obtained from at least three independent experiments are presented as mean ± SD values. To evaluate differences between the two groups, Student’s t-test was carried out, while a one-way ANOVA was utilized to compare multiple groups. A significance level of P < 0.05 was deemed statistically significant. Results TRIM15 expression is upregulated in OC Based on TCGA data, OC tissues exhibited significant upregulation of TRIM15 expression, which was associated with unfavorable prognosis (Fig. 1A, B). Figure 1C showed TRIM15-related DEGs in OC samples. Immunofluorescence analysis confirmed higher TRIM15 protein expression in OC tissues compared to normal tissues (Fig. 1D, E). In conclusion, human OC tissues exhibited a marked elevation in TRIM15 expression. TRIM15 expression exhibits upregulation in OC tissues. (A) Based on GEPIA data, a comparison was made to determine the differential expression of TRIM15 in normal and OC tissues. (B) Kaplan–Meier curves of TRIM15 for OC patients. (C) Expression of tumor-infiltrating immune cells in OC samples. (D, E) Volcano plot and GO enrichment analysis showing DEGs between the high and low TRIM15 expression subgroups in TCGA dataset. (F) Immunofluorescence was used to detect TRIM15 protein expression in ovarian cancer (n = 50) and adjacent tissues (n = 10). Nuclei were stained using DAPI immunofluorescence staining. Scale bars: 50 μm. (G) Quantification of intensity of immunofluorescence of (F). *p < 0.05, **p < 0.01, ***p < 0.001 compared with adjacent tissues TRIM15 mediates the ability of OC cell proliferation and migration in vitro RT-qPCR analysis and Western blotting revealed a significant downregulation of TRIM15 expression in OC cells (OVCAR3 and A2780) transfected with si-TRIM15, in comparison to those transfected with the negative control (si-NC) (Fig. 2A-C). Subsequent functional experiments, including CCK8, clone formation, and Transwell assays, consistently demonstrated that TRIM15 silencing significantly suppressed cell proliferative and migratory abilities in both two OC cell lines (Fig. 2C–H). Enhanced proliferative and migratory abilities were observed in OC cells transfected with TRIM15 overexpression relative to the negative control (Fig. 3A–F). Suppression of OC cell proliferation and migration in vitro by TRIM15 silencing. (A-C) Analysis of siRNA-mediated TRIM15 knockdown efficiency in OVCAR3 and A2780 cells through RT-qPCR (A, B) and WB (C). (D, E) Analysis of cell viability in si-TRIM15 and si-NC transfected OC cells using the CCK8 assay. (F, G) OC cells transfected with si-NC and si-TRIM15 were subjected to colony formation assays. (H, I) Transwell assays were performed to measure the migratory capacity of TRIM15 silencing in OC cells. Scale bar = 100 μm. *p < 0.05, **p < 0.01, ***p < 0.001, compared with si-NC Overexpressed TRIM15 facilitates the proliferative and migratory abilities of OC cells. (A, B) Analysis of cell viability in oe-NC and oe-TRIM15 transfected OC cells using the CCK8 assay. (C, D) OC cells transfected with oe-NC and oe-TRIM15 were subjected to colony formation assays. (E, F) Transwell assays were performed to measure the migratory capacity of TRIM15 overexpression in OC cells. Scale bar = 100 μm. *p < 0.05, **p < 0.01, ***p < 0.001, compared with oe-NC TRIM15 interacts with paxillin To further explore the mechanism of TRIM15, we performed mass spectrometry analysis on immunoprecipitated TRIM15 complexes extracted from OVCAR3 cells. A total of 85 proteins were identified through the combination of iBAQ and unique peptide methods (Table S1, Fig. 4A). Among these proteins, Paxillin exhibited high abundance, and has been confirmed to play a promoting role in ovarian tumor progression [26–28]. As a result, Paxillin was selected as a novel interacting protein with TRIM15. Subsequent immunoprecipitation experiments confirmed the reciprocal interactions between TRIM15 and Paxillin (Fig. 4B). Interestingly, overexpression of TRIM15 resulted in an increased expression in TRIM15 and Paxillin protein level (Fig. 4C–F). These findings indicated that TRIM15 interacted with Paxillin and might enhance Paxillin stability. Fig. 5 illustrated the structural overview and interaction analysis of the PXN-TRIM15 docking model. TRIM15 interacts with Paxillin and enhances Paxillin stability. (A) Flow chart illustrating the LC/MS analysis procedure for identification of TRIM15 downstream targets. (B) Coimmunoprecipitation (co-IP) experiments were conducted to investigate the interaction between TRIM15 and Paxillin in OVCAR3 cells transfected with the specified plasmids. (C–F) Western blot analysis displaying the protein expression levels of TRIM15, Paxillin, and Gapdh in OVCAR3 cells infected with oe-NC or oe-TRIM15. *p < 0.05, **p < 0.01, ***p < 0.001, compared with oe-NC Blind docking analysis of PXN and TRIM15. (A) Docking and confidence for the best complex model. (B) Global view of the best docking complex in surface mode. (C) Cartoon view of the best docking complex with interacting residues highlighted. (D) Interacting links for PXN and TRIM15 TRIM15 facilitates the ubiquitination of paxillin TRIM15, featuring a RING domain, functioned as an E3 ubiquitin ligase, facilitating the ubiquitination of substrate proteins [3]. Consequently, our investigation further explored the potential role of TRIM15 in Paxillin ubiquitination. A subsequent analysis focused on determining the specific ubiquitin chain types of Paxillin influenced by TRIM15. Intriguingly, our findings demonstrated that TRIM15-mediated ubiquitination of Paxillin was associated with Lys11- and Lys29-linked polyubiquitin chains (Fig. 6A). Based on the above results, it was evident that TRIM15 promoted polyubiquitin of Paxillin via Lys11 and Lys29 linkages. TRIM15 promoted polyubiquitin of Paxillin via Lys11 and Lys29 linkages. (A) In screening for potential lysine ubiquitination types, the ubiquitination of Paxillin-GFP in response to TRIM15 overexpression was examined in OVCAR3 transfected with the HA-Ub-K6, K11, K27, K29, K33, K48, and K63 plasmids, and treated with MG132 Overexpression of TRIM15 enhances the interactions between FAK and paxillin Paxillin has multiple phosphorylation sites that are targeted by various kinases [29–31], including FAk and Src-family kinases. Phosphorylation plays a role in enhancing the intricacy of the Paxillin interactome by governing the associations of diverse proteins with its protein-binding modules or, as exemplified by tyrosine phosphorylation, by furnishing supplementary docking sites for additional structural and signaling constituents [30, 32]. Phosphorylated Paxillin (p-Paxillin) has a significant impact on driving the advancement of OC [33, 34]. Interestingly, overexpression of TRIM15 resulted in a noticeable increase in (Tyr118) p-Paxillin protein levels (Fig. 7A, B). FAK is recruited to focal adhesions (FA) through interactions with integrin-associated proteins, including talin and Paxillin [35]. As a cytoplasmic protein-tyrosine kinase, FAK can be activated by integrin clusters, leading to autophosphorylation at Tyr-397 [36]. Extensive research has established Paxillin as a downstream mediator of FAK/p-FAK (Tyr397), which triggers Paxillin phosphorylation (Tyr118) [27, 37, 38]. In our study, co-IP experiments demonstrated a significant increase of the interactions between Paxillin and FAK, or p-FAK (Tyr397) when TRIM15 was overexpressed (Fig. 7C). Overall, overexpression of TRIM15 enhanced the interactions between FAK/p-FAK and Paxillin, consequently promoting Paxillin phosphorylation. TRIM15 enhances the interactions between FAK/p-FAK and Paxillin. (A, B) Western blot analysis displaying the protein expression levels of p-Paxillin (Tyr118) in OVCAR3 (A) and A2780 (B) cells infected with oe-NC or oe-TRIM15. (C) Coimmunoprecipitation (co-IP) experiments were conducted to investigate the interaction between FAK/p-FAK (Tyr397) and Paxillin in OVCAR3 cells transfected with the Paxillin-GFP, Flag-TRIM15, or negative control plasmids Discussion Ubiquitin (Ub) is a regulatory protein with a high degree of conservation, comprising 76 amino acids. Through a sequence of enzymatic reactions involving ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiquitin ligase (E3), Ubiquitin can undergo covalent labeling to selectively target proteins [39, 40]. The process of protein ubiquitination is crucial for the maintenance of cellular homeostasis. Dysregulation of ubiquitin addition or removal can contribute to cancer development, with certain components of the ubiquitination machinery acting as oncogenes [41]. The role of TRIM15, which demonstrates E3 ubiquitin ligase activity, has been well-established as a pro-tumor factor in different types of cancer [42–44], but whether it is relevant to poor prognosis in OC remains unknown. Through bioinformatics analysis, OC tissues exhibited significant upregulation of TRIM15 expression, which was associated with unfavorable prognosis. Our study unveiled increased TRIM15 expression in both human OC tissues and cell lines. Functional experiments exhibited that the inhibition of TRIM15 suppressed the proliferation and migration of OC cells. Overall, the findings indicate that TRIM15 has a promoting effect on the progression of OC. Mass spectrometry analysis of TRIM15 immunoprecipitates identified Paxillin as its interacting protein. Overexpression of TRIM15 resulted in an increase in Paxillin protein levels, a multi-domain protein primarily localized to FA, which are cell adhesion sites connecting the extracellular matrix to the actin cytoskeleton [45–47]. The turnover of FA is crucial for cell migration [48, 49]. TRIM15 has been identified as a component of FA that interacts with Paxillin [50]. Previous studies have implicated Paxillin/p-Paxillin in promoting OC progression [26–28, 33, 34]. Wu et al. found the upregulation in Paxillin gene expression stimulated the proliferation, migration, and invasion of ovarian cancer cells [26]. Meng et al. also reported that Paxillin is a potential prognostic biomarker linked to the infiltration of immune cells in ovarian cancer [28]. It has been reported that YYB-101 effectively suppressed the motility of ovarian cancer cells induced by HGF through the inhibition of paxillin phosphorylation and actin-cytoskeleton rearrangement [33]. Post-translational modifications, including phosphorylation and ubiquitination, regulate Paxillin function, with ubiquitination playing a significant role in its localization, stability, and function [51–53]. RNF5-mediated ubiquitination, rather than initiating Paxillin degradation, prompts the relocation of Paxillin from FA to the cytoplasm [51]. In breast tumor cells, a recent study has discovered a new role for MEKK2 in governing the redistribution of Paxillin through ubiquitination-dependent mechanisms [52]. XRNF185 interacts with Paxillin and facilitates ubiquitination thereof, promoting turnover at FA and facilitating mesodermal cell migration during gastrulation [53, 54]. Given that TRIM15 possesses a RING domain associated with E3 ligase activity, we investigated the ubiquitination mechanism further. Our findings demonstrated that TRIM15 enhanced the ubiquitination of Paxillin proteins, specifically through the Lys 11 and Lys 29 linkages. Different from the well-explored K48 and K63 polyubiquitin chains, the functional significance of K11 and K29 ubiquitin linkages is not well understood, and they appear to play a role in nonproteolytic polyubiquitination pathways [55, 56]. During the initial stage of infection, RNF26 facilitates K11-linked polyubiquitination of MITA, safeguarding it against K48-linked polyubiquitination and degradation. This protective mechanism expedites the prompt activation of type I IFN genes [57]. Smurf1 is involved in the ubiquitination of axin through the Lys 29 (K29)-linked polyubiquitin chain, which does not result in degradation. Instead, it hinders the interaction between axin and the Wnt coreceptor LRP5/6, thereby impacting the phosphorylation of LRP6 and inhibiting Wnt/β-catenin signaling [58]. TRAF4 enhances the ubiquitination of the K27 and K29 junctions within the structural domain of TrkA kinase and leads to an increase in the kinase activity of TrkA, which in turn regulates the tyrosine phosphorylation of TrkA [59]. The EDD E3 ubiquitin ligase promotes the ubiquitination of β-catenin using ubiquitin chains linked through Lys29 or Lys11, which ultimately results in increased stability of β-catenin [60]. Through K11-linked polyubiquitination, Ube2s enhances the stability of β-Catenin, thereby promoting mesendoderm specification and contributing to the development of colorectal cancer [61]. By mediating K29-linked polyubiquitination of c-MYC, HECTD3 plays a role in stabilizing the expression of c-MYC [62]. Our findings lead to speculation that TRIM15 mediates polyubiquitination of Paxillin at K11 and K29 ubiquitin linkages, resulting in enhanced stabilization of Paxillin. We also observed that overexpression of TRIM15 led to an increase in the protein level of p-Paxillin (Tyr118). Paxillin has multiple phosphorylation sites that are targeted by various kinases [32], including FAk and Src-family kinases. Phosphorylated Paxillin regulates multiple protein-binding modules, which engage in interactions with a diverse range of regulatory and structural proteins, acting as a platform for their recruitment. Together, these proteins govern the dynamic processes of cell adhesion, cytoskeletal remodeling, and gene expression that are critical for cell migration and survival [30, 32]. The phosphorylation of Paxillin at Ser-178 by JNK is involved in the migration of bladder tumor epithelial cells [63]. Tyrosine phosphorylation of Paxillin has been demonstrated to play a crucial role in both cell cycle progression and adhesion-dependent functions of leukocytes [64, 65]. Activation of the focal-adhesion complex by fibronectin promotes tyrosine (Tyr118) phosphorylation of Paxillin, leading to increased cell invasiveness in gastric tumor cells [66]. p-Paxillin has a significant impact on driving the advancement of OC [33, 34]. We, therefore, investigated the underlying mechanisms behind the phosphorylation of Paxillin at Tyr118 caused by TRIM15. FA play a crucial role in cell migration by regulating cell-matrix interactions [67]. FAK is recruited to FA through interactions with integrin-associated proteins, including Talin and Paxillin [35]. As a cytoplasmic protein-tyrosine kinase, FAK can be activated by integrin clusters, leading to autophosphorylation at Tyr-397 [36]. Paxillin, an important cytoskeletal protein associated with focal adhesions, provides docking sites for FAK [68]. In turn, FAK can phosphorylate Paxillin (Tyr118) to modulate its function [27, 37, 38]. The phosphorylation of Paxillin catalyzed by FAK regulates tumor angiogenesis, cell survival, and the formation of a complex with steroid receptor coactivators [69]. Multiple studies have indicated that integrin-FAK signaling promotes tumor metastasis by activating various signaling pathways through phosphorylation and protein-protein interactions. These interactions, in turn, trigger the activation of multiple signaling cascades, contributing to tumorigenesis [36]. The interactions between FAK and Paxillin play a crucial role in regulating cell migration and metastasis [70]. Src-mediated phosphorylation of FAK (Tyr925) affects the formation of FAK-Paxillin-vinculin complexes, subsequently activating downstream pathways involved in regulating cell morphology and movement, such as MAPK or the Rho/Rac/Cdc42 cascade [71, 72]. Paxillin serves as a downstream target of FAK and activated FAK [70, 73]. The FAK/p-FAK-Paxillin/p-Paxillin signaling axis has been implicated in the progression of OC [27, 34, 37]. In our study, we observed an enhanced interaction between FAK/p-FAK (Tyr397) and Paxillin (Tyr118) in the presence of TRIM15, implying that TRIM15 is required for FAK-mediated phosphorylation of Paxillin. However, it was still not known whether the TRIM15-mediated ubiquitination of Paxillin is involved in the phosphorylation thereof. Conclusion We demonstrated that TRIM15 promoted the proliferation and migration of OC cells. Mass spectrometry analysis of TRIM15 immunoprecipitations identified Paxillin as its interacting protein. Mechanistically, TRIM15 mediates the polyubiquitination of Paxillin via K11 and K29 ubiquitin linkages. Simultaneously, TRIM15 enhances the binding affinity between FAK/p-FAK (Tyr397) and Paxillin, thereby activating the phosphorylation of Paxillin at Tyr118 and promoting the progression of OC (Fig. 8). This evidence suggests that targeting TRIM15 holds promise as a therapeutic approach to treat OC. Schematic depiction of potential mechanisms by which TRIM15 regulates OC progression. (Drawing by Figdraw; www.figdraw.com) Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements Not applicable. Author contributions SH, XX and XH designed and planned the study and analyzed the data; JX, TW, and FW performed experiments and wrote the manuscript; YZ, ML, YZ, WG, WQ and GF collected clinical samples and conducted experiments. All authors read and approved the final manuscript. Funding This work was supported by Scientific Research Project of Gusu School of Nanjing Medical University (GSKY20210208 and GSKY20210203), Cultivation Special Project of Gusu School of Nanjing Medical University (GSKY20220522), “Science and Education Revitalize Health” Youth Science and Technology Project of Suzhou (KJXW2020028), Special project of diagnosis and treatment technology for key clinical diseases of Suzhou of Jiangsu Province (LCZX202013), and Science and Technology Project of Suzhou of Jiangsu Province (SYS2020175). Data availability The datasets analyzed in the current study are publicly available from their respective sources. The data that support the findings of this study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Jiaqi Xu, Tiantian Wu and Fei Wu contributed equally to this work. Contributor Information Xiaoyan Huang, Email: bbhxy@njmu.edu.cn. Xiaoxue Xi, Email: xixiaoxue@126.com. Shunyu Hou, Email: houshunyu@sina.com. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets analyzed in the current study are publicly available from their respective sources. The data that support the findings of this study are available from the corresponding author upon reasonable request.